Drug intelligence / Profile preview

methylreboxetine

Development stage: Unknown
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Methylreboxetine is a radiolabeled derivative of reboxetine used primarily as a positron emission tomography (PET) ligand for imaging the norepinephrine transporter (NET) in the brain. The compound most commonly referenced as methylreboxetine is [(S,S)-[11C]-O-methylreboxetine], also known as [11C]MeNER or [11C]MRB. It acts as a highly selective ligand for NET and is not used therapeutically but rather in research settings to study NET distribution and occupancy in vivo. Its mechanism of action involves binding to the norepinephrine transporter with high affinity.

Other names: [11C]MeNER[11C]O-methylreboxetine(2S,3S)-[11C]MRB

Targets

NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on methylreboxetine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methylreboxetine.

Explore the full profile